(ILMN) Illumina - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090

Sequencers, Arrays, Reagents, Kits, Services

Life Sciences Tools & Services
Market Cap in USD: 23,077m

IPO / Inception: 2000-07-28
12m vs SPY: -19.0%

EPS (Earnings per Share)

EPS CAGR: -60.17%
EPS Trend: 28.2%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -2.68%
Rev. Trend: -75.7%

Last SUE: 1.05
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	44.7%
Value at Risk 5%th	68.7%
Relative Tail Risk	-6.52%

Reward TTM
Sharpe Ratio	0.18
Alpha	-19.53
CAGR/Max DD	-0.15

Character TTM
Hurst Exponent	0.288
Beta	1.109
Beta Downside	0.973

Drawdowns 3y
Max DD	68.94%
Mean DD	40.91%
Median DD	42.85%

Description: ILMN Illumina January 02, 2026

Illumina (NASDAQ: ILMN) develops and sells sequencing- and array-based platforms and consumables for genomic analysis across a global customer base that includes research institutions, clinical labs, pharma/biotech firms, and consumer-genomics companies. Its product portfolio spans next-generation sequencing instruments, whole-genome and targeted-sequencing kits, genotyping arrays, and non-invasive prenatal testing solutions, supported by reagent kits, flow cells, and library-prep services.

Key recent metrics: 2023 revenue reached $5.6 billion, up ~9 % YoY, driven by a 15 % increase in consumables sales as sequencing-throughput volumes rise. The company’s cost-per-genome has fallen below $200, reinforcing its competitive edge in the rapidly expanding clinical-diagnostics market, where NGS adoption is projected to grow at a CAGR of ~20 % through 2030. A notable sector driver is the surge in personalized-medicine pipelines, which fuels demand for high-throughput, low-error-rate sequencing platforms.

For a deeper, data-focused assessment of Illumina’s valuation dynamics, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (703.0m TTM) > 0 and > 6% of Revenue (6% = 257.2m TTM)

FCFTA 0.16 (>2.0%) and ΔFCFTA 7.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 19.45% (prev 31.85%; Δ -12.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.18 (>3.0%) and CFO 1.12b > Net Income 703.0m (YES >=105%, WARN >=100%)

Net Debt (1.53b) to EBITDA (1.29b) ratio: 1.18 <= 3.0 (WARN <= 3.5)

Current Ratio 1.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (157.0m) change vs 12m ago -1.88% (target <= -2.0% for YES)

Gross Margin 66.20% (prev 63.94%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 70.33% (prev 73.00%; Δ -2.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.16 (EBITDA TTM 1.29b / Interest Expense TTM 125.0m) >= 6 (WARN >= 3)

Altman Z'' 1.42

(A) 0.14 = (Total Current Assets 2.80b - Total Current Liabilities 1.96b) / Total Assets 6.18b

(B) -0.12 = Retained Earnings (Balance) -726.0m / Total Assets 6.18b

(D) -0.19 = Book Value of Equity -736.0m / Total Liabilities 3.80b

Total Rating: 1.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.24

1. Piotroski 8.0pt

2. FCF Yield 4.09%

3. FCF Margin 23.49%

4. Debt/Equity 1.08

5. Debt/Ebitda 1.18

6. ROIC - WACC (= 6.91)%

7. RoE 29.98%

8. Rev. Trend -75.73%

9. EPS Trend 28.22%

What is the price of ILMN shares?

As of January 12, 2026, the stock is trading at USD 141.07 with a total of 1,908,595 shares traded.
Over the past week, the price has changed by -0.18%, over one month by +3.39%, over three months by +48.45% and over the past year by -2.18%.

Is ILMN a buy, sell or hold?

Illumina has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold ILMN.

Strong Buy: 7
Buy: 5
Hold: 11
Sell: 2
Strong Sell: 0

What are the forecasts/targets for the ILMN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	129.1	-8.5%
Analysts Target Price	129.1	-8.5%
ValueRay Target Price	145.9	3.4%

ILMN Fundamental Data Overview January 09, 2026

P/E Trailing = 32.9978
P/E Forward = 30.03
P/S = 5.3817
P/B = 9.6352
P/EG = 0.622
Beta = 1.412
Revenue TTM = 4.29b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 24.60b USD (23.08b + Debt 2.58b - CCE 1.05b)
Interest Coverage Ratio = 8.16 (Ebit TTM 1.02b / Interest Expense TTM 125.0m)
EV/FCF = 24.43x (Enterprise Value 24.60b / FCF TTM 1.01b)
FCF Yield = 4.09% (FCF TTM 1.01b / Enterprise Value 24.60b)
FCF Margin = 23.49% (FCF TTM 1.01b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.98 (Enterprise Value 24.60b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 695.5m (EBIT 1.02b * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.18 (Net Debt 1.53b / EBITDA 1.29b)
Debt / FCF = 1.52 (Net Debt 1.53b / FCF TTM 1.01b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.53% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 30.55% (EBIT 1.02b / Capital Employed (Equity 2.35b + L.T.Debt 994.0m))
RoIC = 16.04% (NOPAT 695.5m / Invested Capital 4.34b)
WACC = 9.13% (E(23.08b)/V(25.65b) * Re(10.0%) + D(2.58b)/V(25.65b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 74.15% ; FCFF base≈822.6m ; Y1≈826.5m ; Y5≈883.5m
Fair Price DCF = 73.26 (EV 12.72b - Net Debt 1.53b = Equity 11.19b / Shares 152.8m; r=9.13% [WACC]; 5y FCF grow 0.0% → 2.90% )
EPS Correlation: 28.22 | EPS CAGR: -60.17% | SUE: -4.0 | # QB: 0
Revenue Correlation: -75.73 | Revenue CAGR: -2.68% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.11 | Chg30d=-0.013 | Revisions Net=+1 | Analysts=11
EPS next Year (2026-12-31): EPS=5.05 | Chg30d=+0.045 | Revisions Net=-1 | Growth EPS=+7.2% | Growth Revenue=+2.3%

Additional Sources for ILMN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle